Biotech

All Articles

Ascendis' dwarfism medicine favorites in phase 3, threatens BioMarin

.Ascendis Pharma has become a possible danger to BioMarin's Voxzogo, disclosing stage 3 development ...

Despite ph. 3 skip, Alkeus finds course in advance for eye disease property

.Though Alkeus Pharmaceuticals' dental eye health condition property fell short to considerably mini...

Kairos goes social with $6M IPO to money trials of cancer cells drug

.With a trio of biotechs hitting the Nasdaq on Friday, it was simple to skip a smaller-scale social ...

Vaccine as well as Keytruda combination reliable in squamous tissue carcinoma

.Immune system gate inhibitors are actually the superheroes of cancer cells treatment. Medicines lik...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of notable management hirings, firings and ...

Regeneron's Opdualag competitor presents 57% action fee

.Regeneron is back along with lasting consequence for its LAG-3 prevention and PD-1 inhibitor combin...

AstraZeneca posts information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early take a look at the functionality of its own in-house antib...

iTeos- GSK's TIGIT star reveals meaningful improvement

.After revealing a period 3 launch based upon beneficial midstage results, iTeos and GSK are lastly ...

More collaborative FDA can increase rare health condition R&ampD: record

.The FDA must be actually a lot more available and also collaborative to discharge a surge in commen...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara The...